Mon Jan 27 05:00:48 UTC 2025: **Biocon’s ESG Score Soars, Reflecting Commitment to Sustainability**
**Bengaluru, India – January 27, 2025** – Biocon Limited, a global biopharmaceuticals company, announced a significant improvement in its Environmental, Social, and Governance (ESG) score, as assessed by S&P Global’s Corporate Sustainability Assessment (CSA). Biocon’s score jumped from 63 in 2023 to 69 in 2024, placing it in the 98th percentile among its global biotechnology peers.
The improvement reflects Biocon’s strengthened performance across all three ESG dimensions: Environmental (76), Social (74), and Governance & Economic (62). Specific advancements were noted in environmental policy, energy efficiency, water management, and human capital management.
Biocon Biologics Limited, a Biocon subsidiary, also participated in the assessment for the first time, achieving an ESG score of 53.
CEO & Managing Director of Biocon Limited, Siddharth Mittal, attributed the improved score to the company’s commitment to embedding sustainable practices throughout its operations, including setting targets for reducing greenhouse gas emissions and freshwater consumption. Shreehas Tambe, CEO & Managing Director of Biocon Biologics Limited, emphasized ESG’s foundational role in the company’s business practices and its dedication to minimizing environmental impact while expanding access to life-saving medicines.
Biocon’s high data availability (90% of required disclosures and 97% of additional disclosures) to S&P Global further underscores its commitment to transparency. The assessment highlighted social dimension, human capital management, and corporate governance as key drivers of Biocon’s improved performance.
First Piper 